TAK-875, a Novel, Orally Available GPR40 Agonist, Augments Glucose-Dependent Insulin Secretion and Improves Both Postprandial and Fasting Hyperglycemia in Type 2 Diabetic Rats

被引：0
|
作者：
Tsujihata, Yoshiyuki
Itou, Ryo
Suzuki, Masami
Harada, Ayako
Negoro, Nobuyuki
Takeuchi, Koji
Yamada, Yukio
Hazama, Masatoshi
机构：
来源：
DIABETES | 2010年 / 59卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A165 / A165
页数：1
相关论文
共 25 条
  • [21] CNX-011-67, a novel GPR40 agonist, enhances glucose responsiveness, insulin secretion and islet insulin content in n-STZ rats and in islets from type 2 diabetic patients
    Venkategowda Sunil
    Mahesh Kumar Verma
    Anup M Oommen
    Manojkumar Sadasivuni
    Jaideep Singh
    Dasarahalli N Vijayraghav
    Bhawna Chandravanshi
    Jayalaxmi Shetty
    Sanghamitra Biswas
    Anilkumar Dandu
    Yoganand Moolemath
    Marikunte V Venkataranganna
    Baggavalli P Somesh
    Madanahalli R Jagannath
    BMC Pharmacology and Toxicology, 15
  • [22] CNX-011-67, a novel GPR40 agonist, enhances glucose responsiveness, insulin secretion and islet insulin content in n-STZ rats and in islets from type 2 diabetic patients
    Sunil, Venkategowda
    Verma, Mahesh Kumar
    Oommen, Anup M.
    Sadasivuni, Manojkumar
    Singh, Jaideep
    Vijayraghav, Dasarahalli N.
    Chandravanshi, Bhawna
    Shetty, Jayalaxmi
    Biswas, Sanghamitra
    Dandu, Anilkumar
    Moolemath, Yoganand
    Venkataranganna, Marikunte V.
    Somesh, Baggavalli P.
    Jagannath, Madanahalli R.
    BMC PHARMACOLOGY & TOXICOLOGY, 2014, 15
  • [23] DS-8500a, an Orally Available G Protein-Coupled Receptor 119 Agonist, Upregulates Glucagon-Like Peptide-1 and Enhances Glucose-Dependent Insulin Secretion and Improves Glucose Homeostasis in Type 2 Diabetic Rats
    Matsumoto, Koji
    Yoshitomi, Tomomi
    Ishimoto, Yoko
    Tanaka, Naomi
    Takahashi, Kanako
    Watanabe, Akiko
    Chiba, Katsuyoshi
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2018, 367 (03): : 509 - 517
  • [24] A randomised, double-blind, placebo- and active-controlled, dose-ranging study to determine the efficacy and safety of the novel GPR40 agonist TAK-875 in subjects with type 2 diabetes mellitus
    Viswanathan, P.
    Marcinak, J.
    Cao, C.
    Xie, B.
    Vakilynejad, M.
    Leifke, E.
    DIABETOLOGIA, 2011, 54 : S85 - S85
  • [25] The Novel, Potent and Orally Available GPR119 Agonist AS1790091 Enhances Insulin Secretion and Insulin Promoter Activity, Preserves B-Cell Function, Improves Insulin Resistance, and Reduces Body Weight Gain in Type 2 Diabetic Mice
    Yoshida, Shigeru
    Tanaka, Hirotsugu
    Oshima, Hiroyuki
    Yonetoku, Yasuhiro
    Ohishi, Takahide
    Matsui, Tetsuo
    Shibasaki, Masayuki
    DIABETES, 2011, 60 : A274 - A275
123